The UK is home to one of the largest gambling markets in the world, generating £14 billion in profit in

From 1 July, psychiatrists in Australia will be able to prescribe MDMA for PTSD and psilocybin for treatment-resistant depression. The

Tryp Therapeutics recently announced interim results from its Phase II trial with psilocybin in the treatment of binge eating disorder,

2023 is expected to be a pivotal year for psychedelic-assisted therapy, with multiple compounds entering the final stages of drug

Awakn Life Sciences announced that its Phase III clinical trial with ketamine-assisted therapy for the treatment of alcohol-use disorder would

On Friday, atai Life Sciences shared results from its Phase IIa trial with PCN-101, R-ketamine, for treatment-resistant depression. Disappointingly, the

The Psychedelics Newsletter is the sector’s best-read investment focused newsletter, with over 25,000 subscribers. Featuring in-depth market analysis and interviews

In the final quarter of 2022, Beckley Psytech shared updates on its drug development pipeline and reported the acquisition of

Despite a challenging economic climate in the latter half of 2022, the year was marked by major milestones in psychedelic

UK-based COMPASS Pathways recently published data from its Phase IIb trials, with COMP360 psilocybin therapy for treatment-resistant depression. This follows

On Tuesday, 29 November, PSYCH released the fourth edition of The Psychedelics as Medicine Report. The report, expanded to include

Veteran affairs receive bipartisan support across North America, with public opinion prompting lawmakers and regulators to support innovations in veteran